CUTANEOUS SQUAMOUS CELL CARCINOMA
Clinical trials for CUTANEOUS SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo tested as new hope for Tough-to-Treat cancers
Disease control TerminatedThis study tested whether adding an experimental drug called SOT101 to an existing immunotherapy (pembrolizumab) could help control advanced cancers that had stopped responding to other treatments. It involved 166 adults with specific advanced solid tumors, including lung, colore…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Cancer drug combo trial halted early
Disease control TerminatedThis study tested whether combining two immunotherapy drugs could help control several types of advanced cancer. It involved 77 people with cancers like skin cancer, lung cancer, and breast cancer. The trial was terminated early because the drug supply was discontinued, so resear…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Early cancer drug trial halted after initial safety testing
Disease control TerminatedThis early-stage study tested a new drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety, how the body processes it, and what side effects it might cause. The trial was termina…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New combo therapy trial for Tough-to-Treat skin cancers
Disease control TerminatedThis study tested whether adding an experimental drug called NT-I7 to an existing immunotherapy (atezolizumab) could help control advanced skin cancers. It focused on patients whose cancers had not responded to or had returned after similar treatments. The main goals were to find…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC